Who
Donald W. DeGolyer
Director
Company insider
Files Form 4 as: Director, Emergent BioSolutions; Director, Tyme Technologies; Chief Operating Officer,Pharma, Endo International; Chief Operating Officer,Pharma, Endo Health Solutions.
In numbers
- Trades disclosed
- 44
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $914K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 26 Feb 2014
- Last trade
- 7 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Oct 2026filed 7 Oct 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $126K17,800 at $7.09 | filing |
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $121K14,527 at $8.36 | filing |
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $8,548954 at $8.96 | filing |
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $121K14,527 at $8.36 | filing |
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $8,548954 at $8.96 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 10 Nov 2025filed 12 Nov 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $188K17,801 at $10.54 | filing |
| 12 Aug 2025filed 13 Aug 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $68K7,844 at $8.65 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,824 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —34,403 at $0.00 | filing |
| 12 Nov 2024filed 14 Nov 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $273K25,000 at $10.91 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,748 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —17,430 at $0.00 | filing |
| 3 Oct 2023filed 5 Oct 2023 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —118,670 at $0.00 | filing |
| 16 Sep 2022filed 16 Sep 2022 | Tyme Technologiesoption or derivative | SEC FORM 4 Code D | —100,000 | filing |
| 16 Sep 2022filed 16 Sep 2022 | Tyme Technologiesoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 16 Sep 2022filed 16 Sep 2022 | Tyme Technologiesoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026Critical Survey: Emergent Biosolutions (NYSE:EBS) & Viridian Therapeutics (NASDAQ:VRDN)EBS · dailypolitical.com · 6 Oct 2026Critical Analysis: Coherus Oncology (NASDAQ:CHRS) and Emergent Biosolutions (NYSE:EBS)EBS · themarketsdaily.com · 5 Oct 2026
0 headlines in the last 90 days name Donald W. DeGolyer; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.